TABLE 2.

Proportion of subjects showing ≥2- or ≥4-fold increase in Ab titer from baseline for each serotype and time point

Vaccine and serotypeTreatment groupFold increase in titer from baseline% of subjects achieving predefined postvaccination titer at:
2 wks4 wks6 wks
Influenza
    A/Brisbane/59/2007Canakinumab≥2100.0100.0100.0
≥4100.0100.096.0
Control≥2100.0100.0100.0
≥4100.0100.0100.0
    A/Uruguay/716/2007Canakinumab≥280.080.080.0
≥472.068.068.0
Control≥288.088.088.5
≥480.068.065.4
    B/Florida/4/2006Canakinumab≥292.088.092.0
≥468.064.064.0
Control≥288.096.092.3
≥476.072.069.2
Meningitis
    MenC (strain C11)Canakinumab≥484.080.080.0
Control≥476.072.069.2